Natalizumab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Natalizumab and local guidelines before prescribing.
Anti-integrin monoclonal antibody
Mechanism
Alpha-4 integrin antagonist blocking leucocyte entry to CNS.
Uses
Relapsing multiple sclerosis, Crohn disease.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Infusion reactions, infection, liver injury, PML.
Interactions
Immunosuppressants increase PML risk.
Contraindications and cautions
PML, active infection
Monitoring
JC virus index, MRI, LFT
Pregnancy and breastfeeding
Limited data
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
JC virus antibody testing and MRI surveillance for PML; patient alert card.
More from the textbook: uses, cautions and other points
- Natalizumab | Infusion (blocks immune cells entering the brain) | PML (brain infection by JC virus) - test for JC virus antibodies and monitor with MRI
Neurology: Anatomy, Physiology and Pharmacology - Avoid MS drugs - interferon beta, natalizumab and fingolimod can make NMOSD worse .
Neurology: Multiple Sclerosis and inflammatory disease - Natalizumab | High efficacy; PML - monitor JCV antibody index and MRI.
Neurology: Multiple Sclerosis and inflammatory disease - Avoid MS DMTs (interferon, natalizumab, fingolimod).
Neurology: Multiple Sclerosis and inflammatory disease - PML (JC virus brain infection) | Natalizumab , rituximab, dimethyl fumarate, other strong immunosuppressants
Neurology: Anatomy, Physiology and Pharmacology - Natalizumab / ocrelizumab / alemtuzumab | MS DMTs; PML (JC virus) / infections, hepatitis B / secondary autoimmunity.
Neurology: Anatomy, Physiology and Pharmacology - Natalizumab (IV or SC every 4–6 weeks) - very effective, but carries a risk of PML (see below).
Neurology: Multiple Sclerosis and inflammatory disease - Natalizumab carries the highest risk - highest in people who are JCV antibody-positive (high index), on treatment for over 2 years, and with previous immunosuppression.
Neurology: Multiple Sclerosis and inflammatory disease
Where it is discussed in the book
- Neurology: Anatomy, Physiology and Pharmacology (3 mentions)
- Neurology: Multiple Sclerosis and inflammatory disease (10 mentions)
- ID: Hospital infection, the immunocompromised host, vaccination and public health (1 mention)
- Clinical imaging: Neuroimaging — head, brain and spine (1 mention)
- Clinical Immunology: Secondary immunodeficiency, the immunocompromised host and vaccination (4 mentions)
- Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology (5 mentions)
- Microbiology: Virology - structure, replication and important viral infections (1 mention)